The HIF pathway as a therapeutic target
- 1 August 2004
- journal article
- review article
- Published by Elsevier BV in Drug Discovery Today
- Vol. 9 (16), 704-711
- https://doi.org/10.1016/s1359-6446(04)03202-7
Abstract
No abstract availableKeywords
This publication has 57 references indexed in Scilit:
- Leu‐574 of human HIF‐1α is a molecular determinant of prolyl hydroxylationThe FASEB Journal, 2004
- Substrate Requirements of the Oxygen-sensing Asparaginyl Hydroxylase Factor-inhibiting Hypoxia-inducible FactorJournal of Biological Chemistry, 2004
- Intracellular localisation of human HIF-1α hydroxylases:implications for oxygen sensingJournal of Cell Science, 2003
- The Selectivity and Inhibition of AlkBPublished by Elsevier BV ,2003
- The antimycotic ciclopirox olamine induces HIF‐1α stability, VEGF expression, and angiogenesisThe FASEB Journal, 2003
- Structural basis for the recognition of hydroxyproline in HIF-1α by pVHLNature, 2002
- Independent function of two destruction domains in hypoxia-inducible factor-α chains activated by prolyl hydroxylationThe EMBO Journal, 2001
- The von Hippel–Lindau tumor suppressor proteinCurrent Opinion in Genetics & Development, 2001
- Salvage angiogenesis induced by adenovirus-mediated gene transfer of vascular endothelial growth factor protects against ischemic vascular occlusionJournal of Vascular Surgery, 1998
- Novel inhibitors of prolyl 4-hydroxylase. 3. Inhibition by the substrate analog N-oxaloglycine and its derivativesJournal of Medicinal Chemistry, 1992